Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
Design Therapeutics (NASDAQ:DSGN), a clinical-stage biotech company focused on developing treatments for degenerative genetic diseases, has announced its participation in the upcoming 2025 Cantor Global Healthcare Conference. The company's management will engage in a fireside chat on September 4, 2025, at 10:55 a.m. ET in New York.
Investors can access the presentation through a live webcast available on the company's website, which will remain archived for at least 30 days after the event.
Design Therapeutics (NASDAQ:DSGN), biotech in fase clinica specializzata nello sviluppo di terapie per malattie genetiche degenerative, parteciper脿 al 2025 Cantor Global Healthcare Conference. Il management terr脿 un fireside chat il 4 settembre 2025 alle 10:55 ET a New York.
Gli investitori potranno seguire la presentazione tramite webcast in diretta sul sito della societ脿; la registrazione rester脿 disponibile in archivio per almeno 30 giorni dopo l'evento.
Design Therapeutics (NASDAQ:DSGN), una biotecnol贸gica en fase cl铆nica dedicada a desarrollar tratamientos para enfermedades gen茅ticas degenerativas, ha anunciado su participaci贸n en la 2025 Cantor Global Healthcare Conference. La direcci贸n de la compa帽铆a participar谩 en un fireside chat el 4 de septiembre de 2025 a las 10:55 a.m. ET en Nueva York.
Los inversores podr谩n acceder a la presentaci贸n mediante un webcast en vivo en la web de la compa帽铆a; la grabaci贸n permanecer谩 archivada al menos 30 d铆as tras el evento.
Design Therapeutics (NASDAQ:DSGN)電� 韲错枆靹� 鞙犾爠 歆堩櫂 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 鞛勳儊 雼硠 氚旍澊鞓ろ厤鞙茧, 雼り皜鞓る姅 2025 Cantor Global Healthcare Conference鞐� 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓 瓴届榿歆勳潃 2025雲� 9鞗� 4鞚� 鞓れ爠 10:55(霃欕秬鞁滉皠) 雺挫殨鞐愳劀 韺岇澊鞏挫偓鞚措摐 毂勴寘鞐� 彀胳棳頃� 鞓堨爼鞛呺媹雼�.
韴瀽鞛愲摛鞚� 須岇偓 鞗轨偓鞚错姼鞐愳劀 鞝滉车霅橂姅 霛检澊敫� 鞗轨簮鞀ろ姼搿� 氚滍憸毳� 鞁滌箔頃� 靾� 鞛堨溂氅�, 頄夓偓電� 膦呺 頉� 斓滌唽 30鞚缄皠 鞎勳勾鞚措笇搿� 鞝滉车霅╇媹雼�.
Design Therapeutics (NASDAQ:DSGN), une soci茅t茅 biotechnologique en phase clinique d茅di茅e au d茅veloppement de traitements pour des maladies g茅n茅tiques d茅g茅n茅ratives, a annonc茅 sa participation 脿 la 2025 Cantor Global Healthcare Conference. La direction tiendra un fireside chat le 4 septembre 2025 脿 10h55 ET 脿 New York.
Les investisseurs pourront suivre la pr茅sentation via un webcast en direct sur le site de la soci茅t茅 ; l'enregistrement restera archiv茅 pendant au moins 30 jours apr猫s l'茅v茅nement.
Design Therapeutics (NASDAQ:DSGN), ein klinisch fortgeschrittenes Biotech-Unternehmen, das Behandlungen f眉r degenerative genetische Erkrankungen entwickelt, k眉ndigt seine Teilnahme an der 2025 Cantor Global Healthcare Conference an. Das Management wird am 4. September 2025 um 10:55 Uhr ET in New York in einem Fireside-Chat auftreten.
Investoren k枚nnen die Pr盲sentation 眉ber einen Live-Webcast auf der Unternehmenswebsite verfolgen; die Aufzeichnung wird mindestens 30 Tage nach der Veranstaltung archiviert bleiben.
- None.
- None.
CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Thursday, September 4, 2025, at 10:55 a.m. ET in New York.
A live webcast of the fireside chat will be available and in the investors section of the company鈥檚 website at . The webcast will be archived for at least 30 days following the presentation.
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC庐 gene targeted chimera small molecules. The company鈥檚 GeneTAC庐 molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC庐 programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in myotonic dystrophy type-1 and Huntington鈥檚 disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Contact:
Renee Leck
THRUST Strategic Communications
听
FAQ
When is Design Therapeutics (DSGN) presenting at the 2025 Cantor Global Healthcare Conference?
How can investors access Design Therapeutics' (DSGN) presentation at the Cantor Conference?
How long will Design Therapeutics' (DSGN) Cantor Conference presentation be available online?
What type of company is Design Therapeutics (DSGN)?
